Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $12.74M rose 70.9% year over year, ahead of the +56.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 56.7% from the prior quarter. Over 3 fiscal years it compounded at +68.8% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +62.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $12.74M+56.7% QoQ
- Last fiscal yearDec 2025
- $30.51M+62.5% YoY
- LTMMar 2026
- $35.8M+56.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +70.9% | -100.0% | -170.9 pp |
| 1 year | +62.5% | -100.0% | -162.5 pp |
| 3-year CAGR | +68.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 30.51M USD
- Year-over-year change
- +62.5%
- 3-year CAGR
- +68.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.51M | +62.5% |
| FY2024 | 2024-12-31 | 18.77M | +102.4% |
| FY2023 | 2023-12-31 | 9.27M | +46.2% |
| FY2022 | 2022-12-31 | 6.34M | — |
Selling, General & Admin vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 selling, general & admin of $35.8M is the 3rd highest of the 6 companies compared; the peer median is $29.66M.
- Its year-over-year change of +56.4% is the 2nd highest of 6, against a peer median of +9.0%.
- Over three fiscal years its annual growth of +68.8% compares with a peer median of +10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $35.8M | +56.4% | +68.8% | — |
| LTM Mar 2026 | $29.66M | +100.0% | +10.0% | 249.6% | |
| LTM Mar 2026 | $18.51M | +10.2% | +13.1% | — | |
| LTM Mar 2026 | $8.11M | +9.0% | +0.2% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $29.66M | +9.0% | +10.0% | 136.9% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| Weighted Avg Shares | 51.76M | 51.76M | 54.42M | 54.68M |
| Weighted Avg Shares (Diluted) | 51.76M | 51.76M | 54.42M | 54.68M |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.